Clinical Trial Update: Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating weekly paclitaxel, carboplatin and irinotecan for lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Irinotecan (Irinotecan)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED